Fandy, Tamer E <br/><br/>
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.  [electronic resource] 

 -  Blood  Sep 2009 
 - 2764-73 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2009-02-203547  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Azacitidine--administration & dosage<br/>Benzamides--administration & dosage<br/>Cytogenetic Analysis<br/>DNA Damage--drug effects<br/>Drug Administration Schedule<br/>Epigenesis, Genetic--drug effects<br/>Female<br/>Hematologic Neoplasms--diagnosis<br/>Humans<br/>Male<br/>Middle Aged<br/>Prognosis<br/>Pyridines--administration & dosage<br/>Time Factors